Clinical trial

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's…

NCT00360568 · AbbVie (prior sponsor, Abbott), Industry · Completed

Key facts

NCT number NCT00360568
Title Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
Official title Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects
Lead sponsor AbbVie (prior sponsor, Abbott), Industry
Collaborators Quintiles, Inc. Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Intervention type Device, Drug
Interventions Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Enrollment 62
Start date Jun 1, 2009
Primary completion Oct 1, 2012
Completion Oct 1, 2012
First posted Aug 4, 2006
Last update posted Jan 16, 2015
Countries Germany, New Zealand, United States

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies